Ironwood Pharmaceuticals Stock Today
| IRWD Stock | USD 3.67 0.15 4.26% |
Performance0 of 100
| Odds Of DistressOver 80
|
Ironwood Pharmaceuticals is trading at 3.67 as of the 28th of November 2024, a 4.26 percent increase since the beginning of the trading day. The stock's lowest day price was 3.52. Ironwood Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Ironwood Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of February 2010 | Category Healthcare | Classification Health Care |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 160.03 M outstanding shares of which 10.96 M shares are currently shorted by private and institutional investors with about 6.44 trading days to cover. More on Ironwood Pharmaceuticals
Moving against Ironwood Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ironwood Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Obamacare Repeal (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, SP Small-Cap 600, Obamacare Repeal, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIronwood Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ironwood Pharmaceuticals' financial leverage. It provides some insight into what part of Ironwood Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ironwood Pharmaceuticals (IRWD) is traded on NASDAQ Exchange in USA. It is located in 100 Summer Street, Boston, MA, United States, 02110 and employs 267 people. Ironwood Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 563.3 M. Ironwood Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 160.03 M outstanding shares of which 10.96 M shares are currently shorted by private and institutional investors with about 6.44 trading days to cover.
Ironwood Pharmaceuticals currently holds about 504.36 M in cash with 183.43 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.29.
Check Ironwood Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Ironwood Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ironwood Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ironwood Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ironwood Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Ironwood Ownership Details
Ironwood Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Kynam Capital Management, Lp | 2024-09-30 | 3.7 M | |
| Geode Capital Management, Llc | 2024-09-30 | 3.3 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.9 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 1.9 M | |
| Ubs Group Ag | 2024-06-30 | 1.8 M | |
| Amvescap Plc. | 2024-06-30 | 1.7 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.6 M | |
| Northern Trust Corp | 2024-09-30 | 1.5 M | |
| Jupiter Asset Management Limited | 2024-09-30 | 1.4 M | |
| Blackrock Inc | 2024-06-30 | 22.9 M | |
| Vanguard Group Inc | 2024-09-30 | 22 M |
Ironwood Pharmaceuticals Historical Income Statement
Ironwood Stock Against Markets
Ironwood Pharmaceuticals Corporate Management
| Thomas McCourt | Chief Commercial Officer and Sr. VP of Marketing and Sales | Profile | |
| Jana Noeldeke | Basel Leader | Profile | |
| Ronald Silver | Corporate Officer | Profile | |
| Marcel Moulaison | Vice Operations | Profile | |
| Beth Calitri | Head Relations | Profile | |
| Sravan Emany | Principal VP | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.